EGFR L858R Citations (19)

Originally described in: Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants.
Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M PLoS Med. 2005 Oct 4. 2(11):e313. PubMed Journal

---

Articles Citing EGFR L858R

Articles
Extracellular signal-regulated kinase 8 (ERK8) controls estrogen-related receptor alpha (ERRalpha) cellular localization and inhibits its transcriptional activity. Rossi M, Colecchia D, Iavarone C, Strambi A, Piccioni F, Verrotti di Pianella A, Chiariello M. J Biol Chem. 2011 Mar 11;286(10):8507-22. doi: 10.1074/jbc.M110.179523. Epub 2010 Dec 28. PubMed
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, Melmed S. J Clin Invest. 2011 Dec;121(12):4712-21. doi: 10.1172/JCI60417. Epub 2011 Nov 21. PubMed
Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, Weiss GJ, Kingsley CB, Loftus JC, Bremner R, Tran NL, Winkles JA. Am J Pathol. 2012 Jul;181(1):111-20. doi: 10.1016/j.ajpath.2012.03.026. Epub 2012 May 23. PubMed
Nickel may contribute to EGFR mutation and synergistically promotes tumor invasion in EGFR-mutated lung cancer via nickel-induced microRNA-21 expression. Chiou YH, Liou SH, Wong RH, Chen CY, Lee H. Toxicol Lett. 2015 Aug 19;237(1):46-54. doi: 10.1016/j.toxlet.2015.05.019. Epub 2015 May 27. PubMed
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H. Elife. 2015 Jun 5;4:e06907. doi: 10.7554/eLife.06907. PubMed
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells. Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5. PubMed
Near Infrared Photoimmunotherapy in a Transgenic Mouse Model of Spontaneous Epidermal Growth Factor Receptor (EGFR)-expressing Lung Cancer. Nakamura Y, Ohler ZW, Householder D, Nagaya T, Sato K, Okuyama S, Ogata F, Daar D, Hoa T, Choyke PL, Kobayashi H. Mol Cancer Ther. 2017 Feb;16(2):408-414. doi: 10.1158/1535-7163.MCT-16-0663. Epub 2016 Nov 15. PubMed
Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kalpha-selective Inhibitors in Breast Cancer. Xu YC, Wang X, Chen Y, Chen SM, Yang XY, Sun YM, Geng MY, Ding J, Meng LH. Theranostics. 2017 Feb 23;7(4):974-986. doi: 10.7150/thno.17830. eCollection 2017. PubMed
A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR. Song X, Qi X, Wang Q, Zhu W, Li J. Am J Cancer Res. 2017 Sep 1;7(9):1884-1898. eCollection 2017. PubMed
MELK expression correlates with tumor mitotic activity but is not required for cancer growth. Giuliano CJ, Lin A, Smith JC, Palladino AC, Sheltzer JM. Elife. 2018 Feb 8;7. pii: 32838. doi: 10.7554/eLife.32838. PubMed
SLC2A5 promotes lung adenocarcinoma cell growth and metastasis by enhancing fructose utilization. Weng Y, Fan X, Bai Y, Wang S, Huang H, Yang H, Zhu J, Zhang F. Cell Death Discov. 2018 Feb 26;4:38. doi: 10.1038/s41420-018-0038-5. eCollection 2018 Dec. PubMed
Upregulation of SALL4 by EGFR activation regulates the stemness of CD44-positive lung cancer. Du W, Ni L, Liu B, Wei Y, Lv Y, Qiang S, Dong J, Liu X. Oncogenesis. 2018 Apr 25;7(4):36. doi: 10.1038/s41389-018-0045-7. PubMed
Direct visualization of single-molecule membrane protein interactions in living cells. Kim DH, Park S, Kim DK, Jeong MG, Noh J, Kwon Y, Zhou K, Lee NK, Ryu SH. PLoS Biol. 2018 Dec 13;16(12):e2006660. doi: 10.1371/journal.pbio.2006660. eCollection 2018 Dec. PubMed
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib: a Brief Report. Castellano GM, Aisner J, Burley SK, Vallat B, Yu HA, Pine SR, Ganesan S. J Thorac Oncol. 2019 Jun 26. pii: S1556-0864(19)30495-2. doi: 10.1016/j.jtho.2019.06.015. PubMed
Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Vaishnavi A, Scherzer MT, Kinsey CG, Parkman GL, Truong A, Ghazi P, Schuman S, Battistone B, Garrido-Laguna I, McMahon M. Cell Rep. 2020 Aug 4;32(5):107994. doi: 10.1016/j.celrep.2020.107994. PubMed
Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. Nishiya N, Oku Y, Ishikawa C, Fukuda T, Dan S, Mashima T, Ushijima M, Furukawa Y, Sasaki Y, Otsu K, Sakyo T, Abe M, Yonezawa H, Ishibashi F, Matsuura M, Tomida A, Seimiya H, Yamori T, Iwao M, Uehara Y. Cancer Sci. 2021 May;112(5):1963-1974. doi: 10.1111/cas.14839. Epub 2021 Mar 24. PubMed
FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment. Song X, Tang W, Peng H, Qi X, Li J. Invest New Drugs. 2021 Oct;39(5):1201-1212. doi: 10.1007/s10637-021-01061-1. Epub 2021 Apr 7. PubMed
USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K. Prieto-Garcia C, Hartmann O, Reissland M, Braun F, Bozkurt S, Pahor N, Fuss C, Schirbel A, Schulein-Volk C, Buchberger A, Calzado Canale MA, Rosenfeldt M, Dikic I, Munch C, Diefenbacher ME. Mol Oncol. 2022 Sep;16(17):3082-3106. doi: 10.1002/1878-0261.13217. Epub 2022 Apr 30. PubMed
Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers. Tsutsumi H, Iwama E, Ibusuki R, Shimauchi A, Ota K, Yoneshima Y, Inoue H, Tanaka K, Nakanishi Y, Okamoto I. Lung Cancer. 2023 Jan;175:101-111. doi: 10.1016/j.lungcan.2022.11.018. Epub 2022 Nov 29. PubMed

If you have published an article using this material, please email us at to have your article added to this page.